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Abstract
Background: Compulsory admission to psychiatric hospital is rising despite serious ethical concerns. Among
measures to reduce compulsory admissions, Psychiatric Advance Directives (PAD) are the most promising, with
intensive PAD (i.e. facilitated and shared) being the most effective. The aim of the study is to experiment Psychiatric
Advance Directives in France.
Methods: A multicentre randomized controlled trial and qualitative approach conducted from January 2019 to
January 2021 with intent-to-treat analysis.
Setting: Seven hospitals in three French cities: Lyon, Marseille, and Paris. Research assistants meet each participant
at baseline, 6 months and 12 months after inclusion for face-to-face interviews.
Participants: 400 persons with a DSM-5 diagnosis of bipolar I disorder (BP1), schizophrenia (SCZ), or schizoaffective
disorders (SCZaff), compulsorily admitted to hospital within the last 12 months, with capacity to consent (MacCAT-
CR), over 18 years old, and able to understand French.
Interventions: The experimental group (PAD) (expected n = 200) is invited to fill in a document describing their
crisis plan and their wishes in case of loss of mental capacity. Participants meet a facilitator, who is a peer support
worker specially trained to help them. They are invited to nominate a healthcare agent, and to share the document
with them, as well as with their psychiatrist. The Usual Care (UC) group (expected n = 200) receives routine care.
Main outcomes and measures: The primary outcome is the rate of compulsory admissions to hospital during the
12-month follow-up. Secondary outcomes include quality of life (S-QoL18), satisfaction (CSQ8), therapeutic alliance
(4-PAS), mental health symptoms (MCSI), awareness of disorders (SUMD), severity of disease (ICG), empowerment
(ES), recovery (RAS), and overall costs.
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Discussion: Implication of peer support workers in PAD, potential barriers of supported-decision making,
methodological issues of evaluating complex interventions, evidence-based policy making, and the importance of
qualitative evaluation in the context of constraint are discussed.
Trial registration: ClinicalTrials.gov identifier: NCT03630822. Registered 14th August 2018.
Keywords: Facilitated psychiatric advances directives, Advance decision making, Supported decision making, Peer
support workers, Compulsory admission
Background
Persons with mental illness can experience fluctuations
in their state of mental health, with their mental capacity
being more or less altered [1]. In cases where the person
becomes incapable of making decisions and needs care,
the use of compulsory care is legally possible and orga-
nized with the objective to prevent self-harm and harm
to others [2]. When compulsory treatment is used, the
principle of benevolence prevails over the principle of
autonomy in the ethical balance of the clinician [3].
However, an increasing number of studies show the im-
portance of autonomy and self-determination in the re-
covery from severe mental disorders [4–8], supported by
the claims of activists and legal texts of human rights
bodies [9]. Furthermore, a growing number of studies
show the harmful impact of compulsory treatment on
the person [10–17]. These two bodies of evidence com-
plicate the assessment of the weight of each ethical argu-
ment and bring many dilemmas [18, 19], but do not
systematically lead to a decrease in this type of measure.
Indeed, a recent review founded an increase in involun-
tary admission in 11 of 18 countries surveyed, including
France [20]. The published rates vary with a ratio of 1 to
19.5 between comparable Western European countries
(i.e. Italy and Austria) [20], and between departments
within the same country (e. g. in France with a ratio of 1
to 6 [21]. Beyond hospitalization, very wide disparities
are observed throughout the field of research on coer-
cion, that depend on culture, mental health legislation,
social context (socioeconomic characteristics, urbanisa-
tion) or service configuration [20, 22].
These disparities do not inhibit action, and the meta-
analysis of de Jong and coll [23]. identified several robust
studies on interventions to reduce compulsory hospital
admission for persons with severe mental illness, with
four main relevant evaluated approaches: advance state-
ments, community treatment orders, compliance en-
hancement, and integrated treatment. Among these
interventions, advance statements were the most prom-
ising, showing a statistically significant and clinically
relevant reduction in compulsory admissions for adults
in psychiatric hospital [23].
In literature, terms “advance statements”; “crisis plan-
ning”, “treatment preferences” and “advance directives”
are found, with advance directives being the widest
spread [20]. Psychiatric advance directives (PADs) are
written documents that allow adults with decision-
making ability to declare their care preferences in ad-
vance, in order for them to be applied in the event of an
impairment of this ability [24]. Specific forms of PADs
are described such as crisis cards, treatment plans, Ulys-
ses Directives, Joint Crisis Plan (JCP), facilitated psychi-
atric advance directives, care plan, advance care plan,
advance decision-making, and the Wellness Recovery
Action Plan (WRAP) [25–31]. All these forms of PAD
have treatment preferences in common but differ in
legal framework, the presence or not of a facilitator, the
sharing conditions, and their content, in particular their
integration in a self-management plan, and the designa-
tion of a health care agent to act on behalf of the person
should he or she be deemed mentally incapable in the
future [32–36]. PADs are considered to be a complex
intervention, with a) several interacting components in-
cluding the document itself, support by the facilitator,
professional and family context, and b) several relevant
levels of implementation including completion of the
document, content of the document, access to directives
by stakeholders and compliance with directives [37].
Considering current literature on the effects of PADs
in reducing compulsory admissions as primary outcome,
five RCTs of high methodological quality were con-
ducted [38–42]. A recent meta-analysis including these
five articles showed a 25% reduction in compulsory ad-
missions for people with PADs compared to usual care
(risk ratio 0.75, 95% CI 0.61–0.93, P = 0.008) [33], with a
greater effectiveness of intensive PADs (i.e. facilitated by
an healthcare agent and shared with caregivers) among
the different models used.
Beyond their effectiveness on constraint, PADs have
shown an improvement of empowerment and self-
determination, awareness, comprehension and appropri-
ation of symptoms and partnership [25, 26, 28, 43–48].
All studies highlight the importance of one-to-one fa-
cilitation to improve drafting, understanding, and shar-
ing of PADs [25, 28, 33].
In France, advance directives were created by the law
of April 22, 2005 and mainly used in end-of-life health-
care [49]. PADs are only marginally used by a few
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pioneering teams. Specifically in Marseille, a group
defending the rights of persons living with mental health
problems has adopted an advance directive document
used in a preliminary study and based on the JCP model.
From there, the group has developed a peer support
practice around the facilitation of PADs in order to
make them more intensive. Introduced in the 1990s in
North American mental healthcare services, peer sup-
port practitioners have experienced mental health chal-
lenges and are trained to support others [50]. They play
a central role in promotion of recovery and recovery-
oriented practices [51]. These PADs have been tested
and improved in Marseille by users, peer-workers and
clinicians, leading to a final version used in this study
protocol.
To our knowledge, no RCT on PADs has ever been
carried out in France.
In order to rigorously evaluate this intervention, a
multicentre, randomized controlled study was designed.
Methods
Aim
The primary objective is to assess the impact of Psychi-
atric Advances Directives (PAD) in comparison with
routine care by a psychiatrist (Usual Care - UC) on the
rate of compulsory admissions to psychiatric hospital
over a 12-month follow-up period.
The secondary objectives are: (1) to assess the impact
of PAD on care-related outcomes (number of inpatient
days, therapeutic alliance), patient reported outcomes
(quality of life, satisfaction), mental-health outcomes (re-
covery, empowerment, awareness of disorders, symp-
tomatology, severity); (2) to measure the cost-
effectiveness and cost-utility of PAD in comparison with
UC; and (3) to describe changes in professional culture
and practices in the different stakeholders, including
users, usual professionals and facilitators.
Design and setting
A multicentre, open-label, randomized, controlled, paral-
lel trial is used to evaluate the effectiveness of PADs. In
parallel, a qualitative study is conducted to document
the recovery trajectories of individuals in the program,
institutional dynamics, and professional practices (in-
cluding facilitator practice) around PADs.
Subjects are referred by their psychiatrists, recruitment
is performed in seven hospitals from three main cities
across France: three Public Institution of Mental Health
in Marseille (AP-HM, Edouard Toulouse, Valvert), two
in Lyon (Le Vinatier, Saint Jean de Dieu ARHM) and
two in Paris (GHU and Argenteuil). Trained research as-
sistants check eligibility criteria, describe the trial, an-
swer any questions the candidates may have and obtain
their written informed consent. Participants are then
randomly assigned to either Psychiatric Advance Direc-
tives (Experimental group) or Usual Care (Control
group) – see Fig. 1. The 1:1 randomization is stratified
per centre and a computer-generated randomization list
is created using a permuted block-design. The statisti-
cian generated the allocation sequence, psychiatrists and
research assistants enrol participants, and research assis-
tants assign participants to the intervention groups ac-
cording to the randomization list.
The organization of the study and its various commit-
tees are represented in Fig. 2.
Inclusion and exclusion criteria
Inclusion criteria are as follows: being over 18 years old;
having a diagnosis of schizophrenia or bipolar I disorder
or schizoaffective disorders according to Diagnostic and
Statistical Manual of Mental Disorders, fifth edition
(DSM-5) criteria; having been involuntarily admitted to
hospital within the past 12 months; having decision-
making capacity, assessed by a psychiatrist according to
the four key components of a capacity evaluation: under-
standing, appreciation, reasoning, and choice, from the
MacArthur Competence Assessment Tool for Clinical
Research (MacCAT-CR) [52]; being covered by French
government health insurance; and speaking French. Ex-
clusion criteria include the following: being considered
unable to provide informed consent and being under
guardianship.
Intervention groups
- Experimental Group: Psychiatric Advance Directives
(PAD). Each person assigned to the experimental group
is invited to fill in a document describing his or her cri-
sis plan and his or her will or preferences in case of be-
ing unable to consent,1 and to meet a facilitator specially
trained to help them with this. He or she is invited to
share the document with his or her psychiatrist and the
reliable person he or she has nominated (a healthcare
agent). Meetings concerning the document between the
peer support worker and the participant take place as
soon as the latter decides to do so, and the support of-
fered lasts as long as necessary. Peer support workers
are recruited specifically for this study, and trained to-
gether for this protocol, on the one hand to ensure both
compliance with the protocol and consistency of
1The document figures in Additional file 1 (in French). It contains the
name and contact of the healthcare agent –the participant’s “reliable
person”, the name of the people to be contacted or not in case of a
crisis, the triggering signs and what helps or does not help at this
stage, what helps in case of a crisis and what does not, the procedure
to be followed in the event of danger, the treatments and others things
accepted during a crisis and those to be avoided, and the choice of
patient care facilities. Objections, values, and principles can also be
stipulated in the document.
Tinland et al. BMC Psychiatry          (2019) 19:422 Page 3 of 13
practice, and on the other hand to better define facilita-
tor practice (what time is needed, what are the obstacles
and enablers). Regular exchanges are organised between
them, and with the entire research team, via web confer-
ences, and regular meetings during the study.
- Control Group: Usual Care (UC). People assigned to
the control group are followed as usual by their
psychiatrist.
No concomitant care or interventions are prohibited
during the trial participation.
Participant time line
Face-to-face interviews to collect quantitative data are
planned with research assistants: inclusion and baseline
interview (M0), 6-month interview (M6) and 12-month
interview (M12) (see Fig. 3).
In the experimental group, research assistants invite
participants to meet the facilitator as soon as possible,
by proposing an immediate phone call to arrange an ap-
pointment. All contact information is provided.
Outcome measures
Primary outcome
The primary outcome is the rate of involuntary admis-
sions to psychiatric hospital at 12 months of follow-up,
from local medical databases, crosschecked and com-
pleted with declarative data, in particular for admissions
in other hospitals (non-local).
Secondary outcomes
– Care-related outcomes:
◦ Number of inpatient days measured both from
local administrative databases and self-reported
data
◦ Perceived coercion, in particular upon
compulsory hospitalization
◦ Therapeutic alliance assessed using the 4-Point
ordinal Alliance Scale (4-PAS) [53]. This self-
rating scale includes two dimensions (empathy
experienced and psychoeducation) and a global
score. Higher scores indicate higher therapeutic
alliance.
◦ Somatic and addictive comorbidity assessed at
baseline by the psychiatrist.
– Patient-reported outcomes:
◦ Quality of life assessed using the
Schizophrenia Quality-of-Life scale (S-QoL
18 scale), which comprises 18 items
evaluating eight dimensions: psychological
well-being, self esteem, family relationships,
relationships with friends, resilience,
physical well-being, autonomy, and
sentimental life [54]. Dimension and index
scores range from 0, indicating the lowest
quality of life, to 100, the highest quality of
life. S-QoL-18 has been validated in bipolar
disorders [55].
Fig. 1 Flow Chart of DAiP Study Design
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◦ Satisfaction of program users evaluated using
the CSQ-8, which is the most frequently used
questionnaire in mental health services [56].
The range is from 8 to 32, with higher scores
indicating higher satisfaction. Satisfaction of
caregivers involved (psychiatrists) is also
assessed using an adaptation of the CSQ-8.
– Mental-health outcomes:
◦ Recovery assessed using the Recovery
Assessment Scale (RAS), which measures
various aspects of recovery from the
consumer’s point of view, with a particular
emphasis on hope and self-determination
[57, 58]. This self-administered instrument
comprises 24 items, exploring five domains:
personal confidence and hope, willingness to
ask for help, goal and success orientation,
reliance on others, and not being dominated
by symptoms. A higher score indicates better
recovery.
◦ Mental health symptomatology assessed using
the self-report Modified Colorado Symptom
Index (MCSI) [59]. This 14-item tool evaluates
how often in the past month an individual has
experienced a variety of mental health
symptoms, including loneliness, depression,
anxiety, and paranoia. Higher scores indicate a
greater likelihood of mental health problems.
◦ Empowerment assessed using the
Empowerment Scale (ES) [60] which is a
specific tool for mental health. It comprises five
dimensions: self-esteem, optimism, power,
activism, and legitimate anger. Higher scores
correspond to higher empowerment.
◦ Awareness of disorders assessed by the
psychiatrist at M0 and M12, using an
abbreviated version of the Scale to Assess
Unawareness of Mental Disorder (SUMD), with
nine items describing three dimensions:
awareness of the disease, consequences and
Fig. 2 DAiP Study Organizational Structure
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need for treatment, awareness of positive
symptoms, awareness of negative symptoms
[61, 62].
◦ Overall severity assessed using Clinical Global
Impression (CGI) [63], where the psychiatrist
rates on a scale from 1 (healthy, not ill) to 7
(severely ill) at M0 and M12.
– Social outcomes:
◦ Gender, age, education level, nationality, social
benefits, wages, employment status, and
housing conditions assessed using ad hoc
questionnaires.
◦ Deprivation assessed at baseline using the
EPICES score (Evaluation of Deprivation and
Inequalities in Health Examination Centres).
This composite index is commonly used to
measure the social and material dimensions of
deprivation [64]. The 11-item version has been
validated on a large cohort [65]. EPICES score is
related to all causes of death, most of the specific
causes of death and to premature and avoidable
deaths. The higher the score, the more deprived
the person is. Authors defined a cutoff value of
30.7 for the threshold defining deprivation.
Fig. 3 Schedule of enrolment, interventions and assessment. SPIRIT diagram of DAiP Study
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– Costs:
◦ Direct and indirect costs are measured during
the 12-month follow-up period. Direct costs
cover the costs related to medical/health
services, including days in hospital, emergency
department visits, and outpatient visits, and
indirect costs mainly related to loss of
productivity. Several sources of data will be
used: local medical databases (Department of
medical information from each centre); medical
records; structured interviews with participants,
as well as the standardized Short Form-Health
and Labor questionnaire (SF-H&L) [66]. The
SF-H&L measures productivity losses caused by
health problems in general: absenteeism from
paid work, production losses without
absenteeism from paid work and hindrance in
the performance of paid and unpaid work.
◦ Cost-utility analysis, measured in quality-
adjusted life years (QALYs), using the EQ5D
scale that applies utility values to each state of
health [67].
Process measurements
Evaluation of the allocation in PAD group (i.e. whether
or not participants have completed the PAD document,
shared them and with whom, met with the facilitator,
and the time spent with the facilitator) is also recorded
in both groups at 6 and 12months. In addition, the soci-
ologist will compare the dynamics between the centres
for the different levels of implementation identified by
Nicaise: completion, content, access and honoring [37].
Sample size
Sample size was calculated to detect a reduction of 30%
in the rate of compulsory admissions to psychiatric hos-
pital during the follow-up period of 12 months between
the two groups (consistent with similar RCTs: 29, 39,
40), with a reference point of 42.6% [68]. To obtain a
significance level of 2.5% and power of 80% with equal
allocation to two arms, each arm of the trial would re-
quire 182 people. To allow for a potential 10% of people
being lost to follow-up, 200 will be recruited per arm,
i.e. 400 in total. Considering the inclusion potential of
each participating centre, inclusion is planned to last for
a 12-month period. The expected period of participation
for each included individual is 12 months.
To promote participant retention, research assistants
were recruited for their interpersonal skills. In addition,
participants will receive €20 for each interview. For
people lost to follow-up, the primary outcome will be
collected from local medical databases.
Statistical analysis
The data will be summarized using the mean, median,
standard deviation and range for quantitative data, and
frequencies for categorical data. Analysis of the primary
and secondary criteria will be performed on the intent-
to-treat population. In addition, complementary per
protocol analyses will be performed.
Comparisons between the two groups for each out-
come will be performed using Student’s t-tests or Mann-
Whitney-Wilcoxon tests for quantitative variables, and
chi-squared or Fisher’s exact tests for proportions. Non-
parametric tests will be used for data that is not nor-
mally distributed. Multivariate analyses will be per-
formed primarily using negative binomial or Poisson
regression models (for overdispersed data) for the num-
ber of involuntary admissions and a gamma distribution
for the number of inpatient days, adjusting for the
lengths of follow-up. Explanatory variables will be se-
lected among those for which the P-value is below or
equal to 0.20 in univariate analysis. The results will be
presented in the form of standardized beta coefficients.
We will use a GEE approach with an exchangeable
correlation matrix, which assumes that patient outcomes
from the same centre are correlated but are independent
from patient outcomes in different centres.
Statistical significance is defined as P < 0.05. Statistical
analyses will be performed using SPSS Statistics for
Windows, Version 20.0 (SPSS Inc. Chicago, IL, USA) or
STATA 16 (StataCorp. 2019. Stata Statistical Software:
Release 16. College Station, TX: StataCorp) LLC.
Cost utility analysis
Health benefits and healthcare costs related to interven-
tions targeted to prevent persons with severe mental ill-
ness from involuntary hospital admissions should be
analysed in order to inform decision makers, psychia-
trists, judges, and relatives of their efficiency [67]. Balan-
cing patient safety with health-related quality of life,
hospital length-of-stay (LOS) and associated costs is vital
[69]. The aim of the economic analysis is therefore to in-
vestigate whether intensive Psychiatric Advance Direc-
tives with the peer support would result in significant
improved health-related quality of life and healthcare
savings compared to usual care.
To quantify the efficiency of PAD from society’s point
of view, we propose to calculate the incremental cost-
utility ratio (ICUR) of the intervention compared to
Usual Care. Incremental benefits will be measured in
quality-adjusted life years (QALYs), which is particularly
relevant here since an expected reduction in involuntary
admission rate associated with enhanced autonomy and
self-determination would have rapid positive impacts on
the patient’s QoL. The time horizon will be 12 months
after randomization.
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QALYs is calculated by multiplying the number of
years of life gained by a health-state associated utility
value (corresponding to patient’s quality of life) during
the period under consideration. Preference-based utility
scores will be calculated using the three-level version of
the EuroQol five-dimensional questionnaire (EQ-5D-3
L). This is a validated questionnaire that assesses a par-
ticipant’s health status in terms of 5 dimensions (mobil-
ity, self-care, routine occupations, pain and discomfort,
and anxiety and depression) [70].
All healthcare resources will be observed, quantified
and value added throughout the period between baseline
and the end of the RCT follow-up. These healthcare
costs will include resources for PAD intervention (in-
cluding professional time and training), in-patient re-
sources (including compulsory and non-compulsory
hospital admissions), outpatient and home care, and
pharmacy claims over the 12-month follow-up period.
Cost resources will be valued using data from the French
National Health system and hospital databases, databases
for medical and paramedical acts, French National offi-
cial list prices for drugs and registers of pharmaceutical
specialities. Indirect costs will be estimated using the SF-
H&L questionnaire but not value added as recom-
mended by the French Health Authority [71].
Sensitivity analysis will be carried out to test the robust-
ness of the results. One-way sensitivity analysis and tor-
nado diagrams will be used to identify thresholds for
factors influencing the ICUR. Probabilistic sensitivity ana-
lysis, using the non-parametric bootstrap method, will be
carried out to generate mean expected ICURs and to de-
termine whether uncertainty or variation in the data affect
ICURs [72]. In addition, cost-effectiveness acceptability
curves will be drawn to represent decision uncertainty
surrounding cost-effectiveness estimates [73].
Qualitative analysis
The qualitative evaluation of the PAD program is carried
out by a sociologist for three groups of stakeholders:
care users, health professionals and institutions. It aims
to understand, from a recovery perspective, the effects of
the program on these different actors. Focus groups and
semi-structured interviews with intervention group par-
ticipants will be done at each site to identify the
organizational and institutional dynamics that are spe-
cific to each centre. There will also be individual inter-
views with psychiatrists, care coordinators, peer support
workers and participants. At least 28 care users (4 per
centre) will be interviewed twice using the life story
method to describe how the PAD program fits into their
trajectory. This evaluation process is combined with a
participatory approach. The various stakeholders are in-
vited to participate in the reflection on the implementa-
tion of the program and its generalization. Inductive
thematic analysis, including constant comparison
methods [73], will be used to analyse data specifically re-
lated to explaining the trial outcomes.
Data management
The data entry is done through an e-CRF (electronic
Case Report Form) developed using the open source
web application REDCap. The access to this application
is secure and is done with a user id and a password.
Each user, and its role in the study, is clearly defined.
Data captured through the software is backed up daily
on a secure network. The database of the study is stored
on a specific directory of the server, administered by the
Digital Services Direction of the sponsor. Data quality is
detailed in data-management and data-validation plans,
approved by the principal investigator of the study. Data
managers structure the data of the included-patients,
and check their coherence and reliability. The data-
manager provides the database to the biostatistician
once it is cleaned and frozen.
The data management and monitoring team will over-
see the intra-study data sharing process. Principal Inves-
tigator will be given access to the cleaned data sets. To
ensure confidentiality, data dispersed to project team
members will be blinded of any identifying participant
information.
Monitoring
In the event of interim analysis or definitive discontinu-
ation of the study, the National coordinating team will
obtain competent authorities the authorisation. As this
research is part of the research involving the human “at
risk and minimal constraints” (categorie 2 in Jardé Law),
and in accordance with the regulations in force, it will
be up to the investigator to declare any serious adverse
event that occurred during the investigations according
to the internal procedure of declaration of a serious ad-
verse event associated with the care of his institution.
The sponsor will conduct study quality monitoring.
The project can be audited by the French competent au-
thority in case of non-respect of the safety or the rights
of the participant.
Dissemination policy
The national coordinating team and the steering com-
mittee will review all presentations and publications be-
fore their publication. All presentations and publications
are expected to protect the integrity of the major object-
ive of the study.
The study results will be released to the participating
psychiatrists, professionals, participants, relevant policy-
makers, and the community through users’ associations.
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Discussion
Advance directives are popular among care users [74],
and seem promising in guiding the mental healthcare
system towards more shared decision-making and more
active participation of care users. We expect that our
study will bring some discussions in France around these
ideas. The role of facilitator has been highlighted to en-
sure the intensity of the PADs, which leads to greater ef-
fectiveness in reducing hospital admissions. Article 12 of
the United Nations (UN) Convention on the Rights of
Persons with Disabilities (CRPD) clearly highlights the
risk of “undue influence” and the need of protection in
supported decision-making, to fully respect rights, will
and preferences [75]. Indeed, coercion in psychiatry in-
cludes compulsion, but also pressure, persuasion, inter-
personal leverage, inducement and threats (“if you refuse
the medication, you will go back to hospital”) [76]. Clas-
sical healthcare professionals or family can easily influ-
ence choices, more or less significantly, and more or less
voluntarily [77, 78]. By employing peer support workers
with own life experience to support the drafting of
PADs, we assume that there is less risk of putting pres-
sure on the person during this exercise with someone
who has personally suffered from coercion and has per-
sonally experienced the importance of personal choice
and responsibility in recovery [79], as is emphasised in
literature on support with decision-making [80].
Potential barriers to PADs include the physician’s atti-
tude, lack of time of professionals, lack of people’s en-
gagement, lack of access to the document during a crisis
or follow-up, inappropriate requests, lack of communica-
tion between carers, or potential conflict of interest be-
tween the physician and the person [81–84]. The
recruitment of a trained facilitator dedicated to this mis-
sion could mediate and overcome a number of these ob-
stacles. However this may be not sufficient because
shared decision-making is described as a process of en-
abling clients to participate actively and meaningfully in
their treatment. This requires accessible information,
choices and integration of care, and therefore the full co-
operation of healthcare professionals. In our study, par-
ticipating psychiatrists are voluntary and theoretically
aware, but are not required to undergo any significant
training or comply with the document. The preliminary
implementation in Marseille enrolled volunteers from a
peer support group, followed by recovery-oriented psy-
chiatrists, and the transfer of this towards a usual setting
could be more challenging than expected.
A sensitive question in this study is linked to the
evaluation of mental capacity, because psychosis and in-
voluntary admission were showed to be the strongest
risk factors for decision-making incapacity [1]. However,
literature shows that mental capacity can be reliably
assessed, even if no gold standard exists as yet [85]. In
this DAiP study, evaluation of competence by a psych-
iatrist with the help of MacCAT-CR is an inclusion cri-
terion. Beyond the baseline assessment, this issue of
decision-making competence is of particular interest and
will be investigated in semi-structured interviews and
focus groups. Indeed, other moral dilemmas may arise in
cases where a person rejects support and/or intimates a
wish to place himself or herself in a situation of danger,
exploitation, abuse or undue influence [86].
The experimental intervention is defined as being a
“complex intervention” [37] i.e. an intervention that in-
volves a number of separate but interacting components
that are likely to be important to the success of the
intervention. If RCTs have been described as being a re-
liable method to evaluate complex interventions [87],
their evaluation raises methodological questions [88]. In
our study, we address this challenge by collecting data
from qualitative and quantitative approaches.
A qualitative approach is also particularly interesting to
supplement the quantitative approach because, as men-
tioned above, constraint is highly influenced by context.
The combination of methods and their triangulation
throughout the research process ensures a more detailed
understanding of the conditions under which PADs can
be deployed in a non-binding legislative context.
Furthermore, this type of research will assess the po-
tential for generalisation of PADs from a public policy
point of view. Indeed, the choice of experimental design
was guided by establishing the highest level of evidence
in order to influence policy decisions (evidence-based
policy making), but RCTs have many blind spots that
can be enlightened by a qualitative approach, e.g. trans-
formation of practices, facilitators and obstacles per-
ceived by the stakeholders.
The question arises of whether such research is neces-
sary since this type of intervention does not basically re-
quire scientific evidence to be implemented. Moreover,
it is already public policy in several countries, such as in
England and Wales (Mental Health Act) or in India (In-
dian Mental Healthcare Act) without being evidence-
based. This highlights the position of this topic at the
crossroads of human rights, science and justice.
Strengths of our research protocol include firstly the
number of participating centres and the number of psy-
chiatrists involved (at least 40) from different back-
grounds, reflecting the diversity of practices in France;
secondly the complementarity of quantitative and quali-
tative approaches with strong collaboration between re-
searchers; thirdly the involvement of care users at
several levels of the study: conception of the document,
construction of the protocol, and peer support work to
help participants from the experimental group.
Limits of the study include firstly the lack of blinding,
which only concerns the primary outcome for participants;
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secondly the implementation in hospitals in large cities,
which may not be representative of smaller hospitals in
smaller cities; thirdly the restriction to 3 types of diagnosis,
which do, however, represent half of the inpatient psychi-
atric treatment in France [13].
To conclude, reducing coercion in mental healthcare
requires urgent mobilization. Psychiatric Advance Direc-
tives drafted with support of a peer-worker could con-
tribute to the necessary cultural change that is needed to
enhance autonomy and self-determination, as inter-
national (UN CRPD) and local human rights defenders
strongly advocate.
Research on interventions to reduce constraint is highly
contextual, influenced by different service configurations,
different mental health laws, different social policies, and
culture [75]. More research on PADs in different contexts
and cultures like the present trial is therefore needed.
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